News | September 16, 2025
Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Subscribe To Our Newsletter & Stay Updated
